Breathe Well Live Well
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
Sacramento Bee One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling … Rigel moving asthma drug into mid-stage trial |
View full post on asthma – Google News
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
MarketWatch (press release) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire via COMTEX/ — Rigel Pharmaceuticals, Inc., (NASDAQ:RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. |
View full post on asthma – Google News
|
Rigel Refuels R&D in $130M Offering
Seeking Alpha Rigel Pharmaceuticals (RIGL) is tapping public investors in a new offering to raise funds for advancing its pre-clinical pipeline, including an asthma drug carried through an early-stage trial by Pfizer (PFE) before it dumped its stake in the program … |
View full post on asthma – Google News
|
Rigel raises $130M for PhII trial of asthma drug
FierceBiotech Pfizer's decision to cut all allergy and respiratory drug development work came as good news for Rigel Pharmaceuticals, even though it meant the end of the two developers' pact for allergic asthma drug candidate R343. Pfizer bought into Rigel's … |
View full post on asthma – Google News
|
Pfizer returns asthma drug development to Rigel
Ventura County Star (AP) – Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage … Rigel Assumes Development Responsibility For Inhaled Asthma Losing Biobucks as Pharma Reshuffles Its Deck Pfizer returns asthma drug candidate rights to Rigel Pharma; latter narrows losses |
View full post on asthma – Google News
|
Rigel Assumes Development Responsibility For Inhaled Asthma
BioResearch Online (press release) South San Francisco, CA /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. … |
View full post on asthma – Google News
|
Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
Medical News Today (press release) Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the … |
View full post on asthma – Google News
|
Pfizer returns asthma drug development to Rigel
BusinessWeek Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage company said … |
View full post on asthma – Google News
|
Pfizer returns asthma drug development to Rigel
Forbes Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage company said … Rigel says Pfizer returns asthma therapy rights Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer returns allergic asthma drug to Rigel |
View full post on asthma – Google News
|
Pfizer returns allergic asthma drug to Rigel
FierceBiotech Pfizer's decision to ends its allergy and respiratory R&D work has prompted the company return rights to the R343 program for allergic asthma to Rigel Pharmaceuticals. The drug has shown promise in Phase I trials and Rigel plans to begin designing a … Rigel says Pfizer returns asthma therapy rights Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer Hands Back Rigel Drug |
View full post on asthma – Google News